Trimetazidine Therapy in Hypertrophic Cardiomyopathy

• Status: Unknown status
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypertrophic cardiomyopathy (HCM) is a common inherited heart condition that causes breathlessness, chest pain and fatigue. There are few treatments available. The investigators have recently shown that a drug called perhexiline reduced symptoms and improved exercise capacity in patients with HCM. This change appears to be driven by alterations in myocardial energy metabolism. The aim of this trial is to test a similar drug, trimetazidine, in a group of symptomatic patients with non-obstructive HCM.

HYPOTHESIS: trimetazidine will improve symptoms, peak oxygen consumption, cardiac function and arrhythmia burden in medically refractory symptomatic patients with non-obstructive HCM.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University College, London
• Collaborator: British Heart Foundation
• Treatments: Trimetazidine

Criteria

Inclusion Criteria:

• Non-obstructive hypertrophic cardiomyopathy (gradient <30 mmHg at rest)

• NYHA (New York Heart Association) Class ≥ 2

• Peak VO2 (maximal oxygen consumption) ≤80% predicted for age and gender

• Heart rate < 90/minute at rest

Exclusion Criteria:

• Diabetes Mellitus

• Abnormal renal function (GFR<60ml/min) or hepatic impairment

• Female who is pregnant, lactating or planning pregnancy during the course of the study